***** seminarMLから情報転載 *****

疾患生命工学センター及び CNBI(ナノバイオ・インテグレーション研究拠点) 共同セミナーのご案内です。

『Pharmacokinetics and pharmacodynamics of an antisense therapeutic: from bench to bedside.
~Exploitng preclinical days for the design and interpretation of clinical trials』

講師:Dr. Arthur A. Levin (Senior Vice President&s_comma; ISIS Pharm. Inc. <http://www.isispharm.com/ >

日時:2007年 4月12日(木) 15:00-16:00

場所:東京大学医学部一号館 講堂(3階)


Antisense (including siRNA) hold great promise as therapeutics because with them it should be possible by targeting mRNA to specifically inhibit the expression many of disease-related proteins . An antisense drug to cytomegaly virus was approved in the United States and Europe in 1999&s_comma; but its use is limited to the eye. Recent advances in antisense technology have greatly facilitated the use of antisense drugs to treat diseases like cancer&s_comma; diabetes and dyslipidemia. The seminar will focus on how chemical modifications to antisense drugs and recent improvements in our understanding of the pharmacokinetics are making the promise of antisense drugs a reality.

講演者経歴紹介 :

Dr. Levin is responsible for all efforts characterizing the toxicity&s_comma; pharmacokinetics and pharmacodynamics of oligonucleotide-based drugs&s_comma; and has been instrumental in the transition of these drugs from basic research to clinical development. Dr. Levin joined Isis in 1995 from Hoffmann-La Roche Inc. where he was Research Leader in retinoid research. Prior to this&s_comma; Dr.Levin held several other research positions at Hoffmann-La Roche in which he established and supervised laboratories dedicated to the research of mechanisms of toxicity&s_comma; biochemical toxicology and toxicokinetics.


URL: http://env-health.m.u-tokyo.ac.jp/seminar_0412.pdf

医学系研究科 疾患生命工学センター 健康・環境医工学部門 遠山千春
E-mail: ctohyama@m.u-tokyo.ac.jp
Tel: 03-5841-1434 (内21434)